- Home
- MRT vs IMMP Comparison
MRT vs IMMP Comparison
Compare MRT & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRT
- IMMP
- Stock Information
- Founded
- MRT 2018
- IMMP 1987
- Country
- MRT Turkey
- IMMP Australia
- Employees
- MRT N/A
- IMMP N/A
- Industry
- MRT Rental/Leasing Companies
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- MRT Consumer Discretionary
- IMMP Health Care
- Exchange
- MRT Nasdaq
- IMMP Nasdaq
- Market Cap
- MRT 228.0M
- IMMP 211.1M
- IPO Year
- MRT N/A
- IMMP N/A
- Fundamental
- Price
- MRT $2.94
- IMMP $1.86
- Analyst Decision
- MRT Strong Buy
- IMMP Buy
- Analyst Count
- MRT 2
- IMMP 1
- Target Price
- MRT $6.00
- IMMP $7.00
- AVG Volume (30 Days)
- MRT 79.7K
- IMMP 726.6K
- Earning Date
- MRT 08-08-2018
- IMMP 02-27-2025
- Dividend Yield
- MRT N/A
- IMMP N/A
- EPS Growth
- MRT N/A
- IMMP N/A
- EPS
- MRT N/A
- IMMP N/A
- Revenue
- MRT $18,659,655.00
- IMMP $3,019,249.00
- Revenue This Year
- MRT $83.29
- IMMP $50.37
- Revenue Next Year
- MRT $106.66
- IMMP N/A
- P/E Ratio
- MRT N/A
- IMMP N/A
- Revenue Growth
- MRT N/A
- IMMP 24.11
- 52 Week Low
- MRT $1.32
- IMMP $1.32
- 52 Week High
- MRT $3.89
- IMMP $3.05
- Technical
- Relative Strength Index (RSI)
- MRT 44.48
- IMMP 48.85
- Support Level
- MRT $2.92
- IMMP $1.88
- Resistance Level
- MRT $3.02
- IMMP $2.05
- Average True Range (ATR)
- MRT 0.19
- IMMP 0.12
- MACD
- MRT -0.03
- IMMP -0.02
- Stochastic Oscillator
- MRT 15.29
- IMMP 9.76
About MRT Marti Technologies Inc.
Marti Technologies Inc is a mobility app, offering multiple transportation services to its riders. Marti operates a ride-hailing service that matches riders with car, motorcycle, and taxi drivers, and operates a large fleet of rental e-mopeds, e-bikes, and e-scooters. All of Marti's offerings are serviced by proprietary software systems and IoT infrastructure.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.